Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian Cancer


Paul A. DiSilvestro, MD, discusses the long-term survival benefit of olaparib maintenance in advanced BRCA-mutated ovarian cancer.

Paul A. DiSilvestro, MD, director, Gynecologic Oncology, the Program in Women’s Oncology, , New England Health System, division director, Gynecologic Oncology, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, discusses the long-term survival benefit of olaparib (Lynparza) maintenance in advanced BRCA-mutated ovarian cancer.

At the 2022 ESMO Congress, investigators presented a 7-year overall survival (OS) analysis of the phase 3 SOLO-1 trial (NCT01844986), which examined olaparib monotherapy vs placebo as maintenance for patients with BRCA-mutated ovarian cancer following a response to first-line chemotherapy.

Patients who achieved a complete or partial response to first-line platinum-based chemotherapy were randomly assigned to olaparib maintenance or placebo, with treatment continuing for up to 2 years or until disease progression, DiSilvestro says. Although the primary end point of the trial was progression-free survival, and OS was a key secondary end point, DiSilvestro explains.

Although 7 years of follow-up have been conducted on SOLO-1, OS events have occurred in only 32.3% of patients in the olaparib arm, DiSilvestro continues. The 84-month OS rate in the olaparib arm was 67%, compared with 46.5% in the placebo arm. With a prespecified OS analysis planned to be conducted when OS data are 60% mature, investigators will need to wait a few more years to find the true OS benefit of olaparib; however, the OS benefit observed so far has been excellent for patients, DiSilvestro concludes.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD